Evidence map›Paper›PMID 34985594›Full record

ArticleInvestigational new drugs2022

AM22, a novel synthetic microRNA, inhibits the proliferation of colorectal cancer cells by targeting core binding factor subunit β (CBFB).

Fanyi Meng, Jiawei Li, Yajing Qiu, Haiyang Zhang, Hongjian Zhang, Weipeng Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fanyi Meng *College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, China.
Jiawei Li *College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, China.
Yajing QiuInstitute of Systems Medicine, Peking Union Medical College Hospital (PUMCH), Suzhou, 215123, China.
Haiyang ZhangCollege of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, China.
Hongjian ZhangCollege of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, China. zhanghongjian@suda.edu.cn.
Weipeng WangCollege of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, China. wangweipeng@suda.edu.cn.ORCID http://orcid.org/0000-0002-3560-204X
Soochow University · CNPeking Union Medical College Hospital · CN

Funding

Jiangsu Provincial Key Research and Development Program BE2019657National Natural Science Foundation of China 81773044
6 · The paper itself

Abstract

Our previous studies have revealed the important roles of the nonseed regions of microRNAs (miRNAs) in gene regulation, which provided novel insight into the development of miRNA analogs for cancer therapy. Here, we altered each nucleotide in the nonseed region of miR-34a and obtained novel synthetic miRNA analogs. Among them, AM22, with a base alteration from G to C at the 17

Indexed as

Colorectal NeoplasmsMicroRNAsAnimalsCell Line, TumorCell ProliferationCore Binding Factor beta SubunitGene Expression Regulation, NeoplasticHumansMiceNucleotidesCBFB protein, humanCore Binding Factor beta SubunitMicroRNAsNucleotidesAntitumor activityCBFBMicroRNASingle nucleotide alterationSynthetic analogs

Identifiers

PMID34985594
OpenAlexW4205535940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.